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Statement of purpose
Harm Reduction Journal (HRJ) is an Open Access, peer-
reviewed international journal of original research and
scholarship on drug use and its consequences for individ-
uals, communities, and larger populations. Its focus is on
reducing the adverse health, social, and political harms
associated with these substances and on the public poli-
cies and strategies in place to control them. We are espe-
cially interested in studies of the evolving patterns of drug
use around the world; the effects of drugs on public health
and the spread of infectious diseases; and accurate
descriptions and rigorous evaluations of innovative poli-
cies and practices for harm reduction in diverse societies.
Audience
In addition to professional practitioners, researchers, and
policy makers working in the drugs field around the
world, Harm Reduction Journal (HRJ) seeks to reach a wider
audience of readers, including university students and
their faculties, journalists, and families seeking accurate
and authoritative information about drugs. The free
online access and links to translated versions of published
peer-reviewed research and other scholarly resources, such
as organizational and government reports, provide the
opportunity to create a new and more accessible interna-
tional standard of publication for research and contempo-
rary thinking about drugs.
Editorial group
The Editorial group can be viewed at http://www.harmre
ductionjournal.com/edboard and includes the Editor-in-
Chief, who will serve as North American Regional Editor
to start, and three Regional Editors.
Content overview
Harm Reduction Journal (HRJ) considers the following
types of articles:
• Research: reports of data from original research and
scholarship.
• Book reviews: 1000–1500 words on recent and classic
works in the field.
• Brief reports: short reports of data from original
research, usually about 1500 words.
• Case reports: reports of clinical cases that can be educa-
tional, describe a diagnostic or therapeutic dilemma, sug-
gest an association, or present an important adverse
reaction.
• Commentaries: short, focused and opinionated articles
on any subject within the journal's scope. These articles
are usually related to a contemporary issue, such as recent
research findings or other HRJ publications. They focus on
specific issues and are about 1500 words.
• Methodology articles: present a new experimental
method, test or procedure. The method described may
either be completely new, or may offer a better version of
an existing method. The article must describe a demon-
strable advance on what is currently available.
• Reviews: comprehensive, authoritative, descriptions of
important subjects within the journal's scope. HRJ will
regularly solicit these and is open to proposals for addi-
tional topics. These have an educational aim and are
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2000–5000 words – with more extensive and wider rang-
ing references.
All articles will be published online immediately upon
acceptance (after peer review) and subsequently listed in
PubMed.
Publishing model
Harm Reduction Journal (HRJ) is published by BioMed
Central, an independent publisher committed to ensuring
peer-reviewed biomedical research is Open Access [1].
That means it is freely and universally accessible online, it
is archived in at least one internationally recognised free
access repository, and its authors retain copyright, allow-
ing anyone to reproduce or disseminate articles, according
to the BioMed Central copyright and licence agree-
ment[2]. HRJ however, has taken this further by making
all its content Open Access.
HRJ's articles are archived in PubMed Central[3], the US
National Library of Medicine's full-text repository of life
science literature, and also in repositories at the University
of Potsdam[4] in Germany, at INIST[5] in France and in e-
Depot[6], the National Library of the Netherlands' digital
archive of all electronic publications.
An article-processing charge must be paid (by the authors,
their institutions, or sponsors) for each published article
to cover the cost of publication and to enable Open
Access. The charge will be waived for the first 6 months of
the journal and, thereafter, for up to 35% of all articles
accepted in order to accommodate work by students and
authors from developing countries. Authors can circum-
vent the charge by getting their institution to become a
'member' of BioMed Central, whereby the annual mem-
bership fee covers the APCs for all authors at that institu-
tion for that year. Current members include NHS
England, the World Health Organization, the US National
Institutes of Health, Harvard, Princeton and Yale universi-
ties, and all UK universities [7]. No charge is made for arti-
cles that are rejected after peer review. Many funding
agencies have also realized the importance of Open Access
publishing and have specified that their grants may be
used directly to pay APCs [8].
Publication languages
Harm Reduction Journal (HRJ) is published in English. If
papers are submitted in other languages and accepted for
publication, a full English translation will be published in
HRJ, accompanied by the original language article (as a
PDF), and by detailed abstracts in other languages as
appropriate. These translations will be linked to the origi-
nal HRJ publication and archived separately, along with a
collection of public access research and documentation of
harm reduction policies and programs, creating a multi-
lingual text of contemporary international scientific evi-
dence on drug use and harm reduction. This is soon to be
available online at http://www.HarmReductionJour
nal.org. This archive will be freely available to drug
researchers, practitioners, policy makers, and students
worldwide. HRJ is a recipient of grants to support this
effort from the Open Society Institute http://
www.sorosny.org and the Baron Edmond de Rothschild
Chemical Dependency Institute of Beth Israel Medical
Center http://opiateaddictionrx.info/index.asp
Peer review policies
• Submitted articles will generally be reviewed by two
external experts. Peer reviewers are asked to indicate
which articles they consider to be especially interesting or
significant. These articles will be given greater prominence
within HRJ and greater external publicity.
• Peer reviewers will have four possible options, for each
article: 1) accept without revision; 2) accept after revision
without expecting to check those revisions; 3) neither
accept nor reject until author(s) make revisions and resub-
mit; 4) reject because scientifically unsound
• Does the article better serve the scientific community? In
the absence of compelling reasons to reject, HRJ advises
that reviewers recommend acceptance, as ultimately the
scientific community will judge the quality of an article
after its publication. Research must be well conceived, rig-
orously executed, and properly interpreted. Results and
conclusions of all articles must be scientifically justified
and not misleading.
• Peer reviewers are asked to indicate if the article is not
clearly written for publication. In such cases authors are
asked to revise the article, seeking, if necessary, the assist-
ance of colleagues or a commercial editing service. HRJ
normally allows authors a maximum of two article revi-
sions. Revisions are typically either for authors tightening
their arguments based on existing data, or identifying
areas where more data are needed.
• We aim to publish research as quickly as possible. Our
electronic submission process is designed to facilitate
rapid publication.
Conclusion
Harm Reduction journal (HRJ) provides an Open Access
forum, serving the community and aiding scientific
research. We hope you will support this by submitting
your next article to HRJ  at http://www.harmreduction
journal.com/manuscript.
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